News Release

THT 2025 late-breaking clinical science unveiled

Cutting-edge heart failure research and innovations coming to Boston, February 11–13

Meeting Announcement

Cardiovascular Research Foundation

NEW YORK – February 5, 2025 – The full lineup of late-breaking clinical science to be presented at THT 2025: Technology and Heart Failure Therapeutics is now available online. Organized by the Cardiovascular Research Foundation® (CRF®), this premier international heart failure conference will be held February 11-13, 2025, at the Omni Boston Hotel at the Seaport in Boston, MA. The full program guide can be found at: https://tht2025.crfconferences.com/program-guide.

Now in its fourth year, THT has established itself as a cornerstone in the pursuit of groundbreaking solutions for heart failure treatment. THT 2025 is poised to deliver an unparalleled experience, spotlighting transformative advancements in device- and technology-based therapies alongside drug treatments, setting the standard for advancing patient care and shaping the future of cardiovascular medicine. Designed by an exceptional lineup of program directors, this year’s agenda features exclusive first-release data from pivotal studies, dynamic discussions on controversies in clinical trials, and deep dives into cutting-edge innovations.

The program includes four dedicated sessions with 21 late-breaking clinical science presentations, highlighting transcatheter approaches to managing a wide spectrum of heart failure patients.

Late-Breaking Clinical Science I

Tuesday, February 11, 2025

9:30 AM — 10:45 AM EST

Ensemble A-B | Level 2

Robotic Surgical Technique for Performing Heart Transplant

Feras Khaliel

Left Atrial to Coronary Sinus Shunting In Heart Failure With Mildly Reduced Or Preserved Ejection Fraction: The ALT FLOW Trial (Early Feasibility Study) 2-Year Results

Javed Butler

Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve Decongestion Management System (DMS) – The FASTR Trial

James E. Udelson

Incidence and Outcome of Early and Late Right Ventricular Failure in Patients with the HeartMate 3 LVAD: A MOMENTUM 3 Analysis

Gabriel Sayer

Changes in Seated Pulmonary Artery Pressure in Response To Titration Of Heart Failure Medications During Ambulatory Monitoring

Sandip K. Zalawadiya

Impact of Obesity Severity on the Effects of Tirzepatide in HFpEF: The SUMMIT Trial

Barry Borlaug

 

Late-Breaking Clinical Science II

Tuesday, February 11, 2025

5:45 PM — 6:45 PM EST

Ensemble A-B | Level 2

Predictors of Improved vs. Worsened Outcomes After Inter-atrial Shunt Treatment in HFrEF and HFpEF: The RELIEVE-HF Trial

Gregg W. Stone

Right Ventricular to Pulmonary Artery Coupling and Clinical Outcomes after Interatrial Shunting in Heart Failure

Stefan Anker

Atrial Shunt for Heart Failure with Preserved and Mildly Reduced Ejection Fraction: Five-Year Outcomes in the REDUCE LAP-HF II Trial

Sanjiv J. Shah

Duration of Heart Failure, Cardiac Dysfunction and Remodeling, and Response to Atrial Shunt Treatment in HFpEF and HFmrEF

Barry Borlaug

Cardiac Microcurrent Application for the Reversal of Heart Failure

Eduardo Rame

 

Late-Breaking Clinical Science III

Wednesday, February 12, 2025

8:00 AM — 9:12 AM EST

Ensemble A-B | Level 2

Safety and Efficacy of the preCARDIA System to Mechanically Reduce Cardiac Preload for Acutely Decompensated Heart Failure: The Expanded VENoUS Heart Failure (VENUS-HF) Early Feasibility Study

Navin K. Kapur

Limited Myocardial Necrosis with Intracoronary Supersaturated Oxygen Therapy In Acute Anterior Myocardial Infarction: Initial Experience In Routine Practice

Andreas Schafer

Lower Extremity Lymphatic Flow Is Associated With Diuretic Response And Weight Change (Decongestion) In Acute Heart Failure

Jan Biegus

Transcatheter Pulmonary Artery Banding [PAB] For HFrEF: Two Year Follow Up And Invasive Exercise Hemodynamics From The Ongoing First-In-Human Trial

Sean P. Pinney

A Digital Platform to Optimize Guideline Directed Heart Failure Therapy: Primary Results of the AIM-POWER Randomized Controlled Trial

Akshay Desai

Burst Steroid Therapy and Quality of Life in Patients with Acute Heart Failure: Insights From the CORTAHF Trial

Matteo Pagnesi

 

Late Breaking Clinical Science IV

Thursday, February 13, 2025

7:00 AM — 8:00 AM EST

Ensemble E-F | Level 2

GSN Ablation Reduces Estimated Stressed Blood Volume in HFpEF: Supports REBALANCE-HF Mechanism of Action

Marat Fudim

Real-World Survival Comparison of Symptomatic Patients with Heart Failure Treated with Cardiac Contractility Modulation (CCM) vs. Cardiac Resynchronization Therapy (CRT)

Andrew Sauer

Impact Of Preoperative Temporary Mechanical Circulatory Support On Durable LVAD Outcomes: An Analysis of the Society Of Thoracic Surgeons National Intermacs Database

Manreet Kanwar

Mitigating Post-Operative Right Ventricular Dysfunction After Left Ventricular Assist Device: The RV Protection Study

Anthony Kanelidis

PICS: A Novel Temporary CV Support Device Augmenting BP and Flow

Alex M. K. Rothman

Additional information on THT is available at https://tht2025.crfconferences.com/.

WHY:

Approximately 6.7 million adults in the United States have heart failure. The incidence of heart failure is projected to increase by 46% from 2012 to 2030, affecting more than 8 million people.

In response to this growing health challenge and the rapid advancements in new therapies, CRF® is committed to providing a premier research and educational platform. THT 2025 is designed to showcase cutting-edge diagnostic approaches and advanced technologies for treating diverse forms of heart failure, driving innovation and improving patient outcomes.

WHEN:         

February 11-13, 2025

WHERE:

Omni Boston Hotel at the Seaport

450 Summer Street

Boston, MA 02210

HOW TO REGISTER:

Media may apply for registration by emailing jromero@crf.org.

About CRF® 

The Cardiovascular Research Foundation® (CRF®) is a global leader in interventional cardiovascular medicine, driving innovation, spearheading groundbreaking research, and transforming education in the field. Through its relentless pursuit of excellence, CRF® not only accelerates medical breakthroughs but also equips healthcare professionals with the tools and knowledge necessary to enhance survival rates and elevate the quality of life for millions worldwide. CRF’s centers of excellence include the CRF Skirball Center for Innovation, CRF Clinical Trials Center, CRF Center for Education, CRF Digital, TCTMD, and Structural Heart: The Journal of the Heart Team. For more information, visit www.crf.org.

###


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.